Thermo Fisher's updated 2025 guidance shows a $1 EPS, or 4.2% hit from tariffs and government spending cuts. Thermo can mitigate the tariff issues by next year, as its scale gives it options to source from different locations. Despite short-term challenges, Thermo Fisher aims for 7-9% long-term sales growth, leveraging its diverse product range and strategic acquisitions.
TMO continues to advance its growth strategy and trusted partner status with customers in the first quarter of 2025.
Thermo Fisher Scientific (TMO) shares rose Wednesday after the lab equipment and life science solutions firm reported first-quarter results above analysts' expectations.
Thermo Fisher Scientific Inc. (NYSE:TMO ) Q1 2025 Earnings Conference Call April 23, 2025 8:30 AM ET Company Participants Rafael Tejada - Vice President, Investor Relations Marc Casper - Chairman, President & Chief Executive Officer Stephen Williamson - Senior Vice President & Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Matt Sykes - Goldman Sachs Jack Meehan - Nephron Research Rachel Vatnsdal - JPMorgan Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Operator Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2025 First Quarter Conference Call. [Operator Instructions] I would like to introduce our moderator for the call, Mr.
While the top- and bottom-line numbers for Thermo Fisher (TMO) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.15 per share, beating the Zacks Consensus Estimate of $5.10 per share. This compares to earnings of $5.11 per share a year ago.
Get a deeper insight into the potential performance of Thermo Fisher (TMO) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher Scientific shows strong fundamentals, consistent earnings growth, and solid financial health, making it a viable long-term investment. TMO's recent product expansion, including the breakthrough Krios 5 Cryo-TEM technology, is expected to drive future growth and support earnings. Valuation metrics indicate TMO is currently undervalued.
TMO continues to hold on to investors' attention due to its value-added acquisitions and trusted end-market channels.
TMO and CZ Imaging Institute to collaborate on further understanding of human cells.
Thermo Fisher introduces the Vulcan Automated Lab to transform semiconductor analysis.